Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment
Rhea-AI Summary
Clearmind Medicine (Nasdaq: CMND) announced a peer-reviewed review published Dec 2, 2025 in Current Addiction Reports evaluating its proprietary candidate MEAI (CMND-100) for alcohol use disorder (AUD).
The review, led by experts including Anahita Bassir Nia from Yale, examines MEAI's pharmacology, receptor interactions, preclinical efficacy, and emerging clinical observations, and positions MEAI as a potential AUD treatment with milder subjective effects and lower cardiovascular, neurotoxicity, and abuse potential than MDMA and classic psychedelics. Recreational dosing reported at 1–2 mg/kg orally with positive effects around 4 hours is cited. The review notes no serious adverse events reported by recreational users but highlights there are no published human adverse‑effect studies to date, while receptor data suggest reduced 5-HT2A/2B/2C activity and no 5-HT2B calcium flux agonism.
Positive
- Peer-reviewed review published on Dec 2, 2025
- Yale-led authorship increases scientific visibility
- Recreational reports: 1–2 mg/kg oral dose with effects at ~4 hours
- Receptor data indicate lower 5-HT2A/2B/2C interaction than MDMA
Negative
- No published human adverse‑effect studies to date
- Clinical evidence limited to emerging data and recreational reports
Key Figures
Market Reality Check
Peers on Argus 1 Up
CMND’s setup appears stock-specific. Among high-affinity biotech peers, moves were mixed, with declines in names like SXTP (-10.82%) and KTTA (-2.61%), while PLRZ gained 13.7%. Momentum scanners only flagged ARTL at +4.49%, so there was no broad sector swing mirroring CMND.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Reverse share split | Negative | -6.1% | Announcement of 1-for-40 reverse split to address Nasdaq bid-price rules. |
| Dec 05 | Listing compliance notice | Negative | +2.5% | Nasdaq minimum $1.00 bid-price noncompliance and 180-day cure period. |
| Dec 02 | Clinical dosing update | Positive | -9.9% | First participant enrolled and dosed in Phase I/IIa CMND-100 AUD trial. |
| Dec 01 | Clinical milestones | Positive | -6.9% | Positive first-cohort data, DSMB continuation, and new elite trial site. |
| Nov 25 | Site activation | Positive | -19.4% | First patient enrollment at Tel Aviv Sourasky in multinational AUD trial. |
Across 5 prior events, 4 showed price moves that diverged from headline tone, including repeated selloffs on positive clinical updates and a decline on reverse-split news.
Over recent weeks, Clearmind has combined financing and listing-compliance steps with steady clinical progress. Multiple Phase I/IIa updates for CMND-100 in Alcohol Use Disorder highlighted positive safety, preliminary efficacy, and new trial sites at institutions such as Hadassah and Tel Aviv Sourasky, yet shares often fell after these announcements. Separately, the company disclosed Nasdaq bid-price noncompliance and a planned 1-for-40 reverse split effective Dec 15, 2025. Today’s expert review of MEAI’s potential fits into this broader effort to validate its AUD program amid ongoing market and listing pressures.
Market Pulse Summary
This announcement spotlights an expert, peer-reviewed evaluation of MEAI for Alcohol Use Disorder, emphasizing its receptor interaction profile, reported lack of serious adverse events in recreational use, and potentially lower abuse and cardiovascular risks versus MDMA and classic psychedelics. Placed alongside recent Phase I/IIa trial progress and capital-raising activity, the news highlights growing external validation of Clearmind’s AUD approach. Investors may monitor future clinical readouts, regulatory milestones, and additional independent data as key markers of program credibility.
Key Terms
alcohol use disorder medical
AI-generated analysis. Not financial advice.
Vancouver, Canada, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of a review article validating the therapeutic promise of its proprietary candidate, MEAI (5-methoxy-2-aminoindane, also known as CMND-100), in combating alcohol use disorder (AUD).
Entitled "The Potential Therapeutic Effects of MEAI in the Treatment of Alcohol Use Disorder", the peer-reviewed review was published on December 2, 2025, in Current Addiction Reports, a respected Springer Nature journal advancing evidence-based addiction research. Authored by a group of experts led by Anahita Bassir Nia from Yale School of Medicine, the article rigorously examines MEAI's pharmacological profile, receptor interaction profile, preclinical efficacy, and emerging clinical data. The article also compares MEAI with classical psychedelics such as LSD and psilocybin and the entactogen MDMA, all investigated to treat AUD. The article positions MEAI to potentially offer a treatment for AUD, with milder subjective experience and less cardiovascular, neurotoxicity, and abuse potential compared to MDMA and other psychedelics. "We believe that this publication elevates MEAI's visibility and awareness within the medical community, drawing attention from leading experts at premier medical centers who are also actively investigating its groundbreaking potential," said Dr. Adi Zuloff-Shani, Ph.D., CEO of Clearmind Medicine. "Due to its receptor interaction profile, MEAI holds the potential to curb cravings and normalize mood without hallucinogenic effects or high abuse liability, and as such to address core unmet needs in AUD treatment. We believe this review reinforces our data-driven path forward."
Highlights from the Review:
- Therapeutic Effects for AUD: Recreational users usually take MEAI orally in amounts ranging from 1 to 2 mg/kg body weight per session. They report feeling positive effects within 4 hours, including a decreased desire to drink alcohol, which has been the basis of the potential use of MEAI to prevent excessive drinking.
- Receptor Interaction Profile: The aminoindane family acts as substrate-type monoamine releasers, showing varying degrees of selectivity for SERT, NET, and DAT. These substances stimulate the release of serotonin and have empathogenic, entactogenic, and mild stimulation effects. Substances that produce non-selective or serotonin-selective neurotransmitter-releasing effects are less prone to abuse and may explain the lower abuse liability of entactogens.
- Adverse effects: Recreational users of MEAI did not report any serious adverse events, although one individual did not enjoy the experience. There are no published studies on MEAI's adverse effects in human volunteers, but based on its receptor interactions, MEAI is expected to have less frequent adverse effects and milder toxicity compared to MDMA. Due to less interaction with 5-HT2A, 5-HT2B, and 5-HT2C, compared to MDMA, fewer cardiovascular and psychological adverse effects are expected. A major finding about the interaction of MEAI with 5-HT2B receptors was that, although it shows some affinity, it does not act as a calcium flux agonist for this receptor.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses how MEAI may potentially offer a treatment for AUD, with milder subjective experience and less cardiovascular, neurotoxicity, and abuse potential compared to MDMA and other psychedelics, how MEAI has the potential to curb cravings and normalize mood without hallucinogenic effects or high abuse liability, and as such to address core unmet needs in AUD treatment and the Company’s data-driven path forward. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What did Clearmind announce about MEAI (CMND) on December 12, 2025?
How does the review describe MEAI's safety compared with MDMA or psychedelics for CMND investors?
What clinical or dosing information about MEAI does the review provide for CMND stakeholders?
Does the review report any serious adverse events for MEAI that could affect CMND development timelines?
Who authored the MEAI review and why does that matter for CMND visibility?
